Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Roehnisch, Tim ^a   Then, Cornelia ^a   Nagel, Wolfgang ^b   Blumenthal, Christina ^a   Braciak, Todd ^a   Donzeau, Mariel ^c   Böhm, Thomas ^a   Bourquin, Carole ^d   Oduncu, Fuat ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Centre National de la Recherche Scientifique Université de Strasbourg   (France)

^d UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

B cell lymphoma; KLH; Murine BCL1 lymphoma model; Phage idiotype vaccination

Indexed keywords

CANCER VACCINE; COAT PROTEIN; IMMUNOGLOBULIN G; KEYHOLE LIMPET HEMOCYANIN; PHAGE IDIOTYPE VACCINE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ENGINEERING; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTECTION; VIRUS PARTICLE; WILD TYPE;

ANIMALS; ANTIBODY FORMATION; BACTERIOPHAGES; CANCER VACCINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LYMPHOMA, B-CELL; MICE;

EID: 84885985306     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-267     Document Type: Article

References (36)

1. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012, 366:2008-2016. 10.1056/NEJMct1114348, 22621628.
2. Lopez-Requena A, Burrone OR, Cesco-Gaspere M. Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol 2012, 2:159. 3493989, 23162790.
3. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171-1177. 10.1038/13928, 10502821.
4. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004, 22:4717-4724. 10.1200/JCO.2004.06.003, 15483014.
5. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009, 9:675-681. 10.1038/nrc2717, 19701243.
6. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011, 29:2787-2794. 10.1200/JCO.2010.33.3005, 3139394, 21632504.
7. Schmitz U, Versmold A, Kaufmann P, Frank HG. Phage display: a molecular tool for the generation of antibodies--a review. Placenta 2000, 21:S106-112. Suppl A.
8. Gaubin M, Fanutti C, Mishal Z, Durrbach A, De Berardinis P, Sartorius R, Del Pozzo G, Guardiola J, Perham RN, Piatier-Tonneau D. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 2003, 22:11-18. 10.1089/104454903321112451, 12590733.
9. Prisco A, De Berardinis P. Filamentous bacteriophage fd as an antigen delivery system in vaccination. Int J Mol Sci 2012, 13:5179-5194. 10.3390/ijms13045179, 3344273, 22606037.
10. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999, 93:2411-2419.
11. Sambrook JFE, Maniatis T. Molecular Cloning, A Laboratory Manual 1989, Cold Spring Harbor, NY: Cold Spring Harbor Laboratories.
12. Bordier C. Phase separation of integral membrane proteins in triton X-114 solution. J Biol Chem 1981, 256:1604-1607.
13. George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987, 138:628-634.
14. Donzeau M, Bauersachs S, Blum H, Reichelt P, Rohnisch T, Nagel W. Purification of his-tagged hybrid phage antibody. Anal Biochem 2006, 352:154-156. 10.1016/j.ab.2005.12.020, 16464434.
15. Krolick KA, Isakson PC, Uhr JW, Vitetta ES. Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody. J Immunol 1979, 123:1928-1935.
16. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature 1978, 272:624-626. 10.1038/272624a0, 306069.
17. Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW. Tumor dormancy and cell signaling: V. regrowth of the BCL1 tumor after dormancy is established. Blood 1997, 89:4425-4436.
18. De Berardinis P, D'Apice L, Prisco A, Ombra MN, Barba P, Del Pozzo G, Petukhov S, Malik P, Perham RN, Guardiola J. Recognition of HIV-derived B and T cell epitopes displayed on filamentous phages. Vaccine 1999, 17:1434-1441. 10.1016/S0264-410X(98)00377-6, 10195779.
19. Barbas CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 1991, 88:7978-7982. 10.1073/pnas.88.18.7978, 52428, 1896445.
20. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993, 217:228-257.
21. van Houten NE, Zwick MB, Menendez A, Scott JK. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 2006, 24:4188-4200. 10.1016/j.vaccine.2006.01.001, 1974903, 16488517.
22. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein. J Immunol 1987, 138:1289-1296.
23. Caspar CB, Levy S, Levy R. Idiotype vaccines for non-hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 1997, 90:3699-3706.
24. Navarrete MA, Heining-Mikesch K, Schuler F, Bertinetti-Lapatki C, Ihorst G, Keppler-Hafkemeyer A, Dolken G, Veelken H. Upfront immunization with autologous recombinant idiotype fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood 2011, 117:1483-1491. 10.1182/blood-2010-06-292342, 21045197.
25. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000, 27:598-613.
26. Abdalla AO, Kokhaei P, Hansson L, Mellstedt H, Osterborg A. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol 2008, 19:1172-1179. 10.1093/annonc/mdn017, 18272909.
27. De Berardinis P, Sartorius R, Fanutti C, Perham RN, Del Pozzo G, Guardiola J. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat Biotechnol 2000, 18:873-876. 10.1038/78490, 10932158.
28. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999, 162:4790-4795.
29. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, Vitetta ES. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258. 10.1038/334255a0, 2456466.
30. Kanai N, Min WP, Ichim TE, Wang H, Zhong R. Th1/Th2 xenogenic antibody responses are associated with recipient dendritic cells. Microsurgery 2007, 27:234-239. 10.1002/micr.20342, 17477419.
31. Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma-evaluation of T-cell responses by different read-out systems. Haematologica 2007, 92:110-114. 10.3324/haematol.10095, 17229643.
32. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 2007, 13:1503-1510. 10.1158/1078-0432.CCR-06-1603, 17332295.
33. Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990, 76:2599-2605.
34. Celsing F, Hast R, Stenke L, Hansson H, Pisa P. Extramedullary progression of multiple myeloma following GM-CSF treatment-grounds for caution?. Eur J Haematol 1992, 49:108.
35. Sartorius R, Bettua C, D'Apice L, Caivano A, Trovato M, Russo D, Zanoni I, Granucci F, Mascolo D, Barba P, et al. Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants. Eur J Immunol 2011, 41:2573-2584. 10.1002/eji.201141526, 21688262.
36. van Houten NE, Henry KA, Smith GP, Scott JK. Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine 2010, 28:2174-2185. 10.1016/j.vaccine.2009.12.059, 2830289, 20056188.